CETP Genotype (p.Arg468Gln)

Most people learn whether their HDL (the so-called good cholesterol) is high or low only after a blood draw. This test answers a different question: did you inherit a version of a key cholesterol-shuffling gene that quietly pushes your HDL down and changes how your body behaves under serious stress like sepsis?

The variant tested here, p.Arg468Gln (also written rs1800777), is a gain-of-function change in the CETP gene. It does not change over your lifetime, and it will not show up on a standard lipid panel as a single number. But it sits upstream of your HDL number and has been linked to worse outcomes during severe infection in human studies.

What This Gene Actually Does

CETP (cholesteryl ester transfer protein) is made mostly in your liver and floats through your blood attached to lipoproteins. Its job is to move cholesterol from HDL particles over to LDL and VLDL particles. The more active your CETP, the lower your HDL tends to be and the more cholesterol ends up in the LDL particles that drive plaque buildup.

The p.Arg468Gln variant is a missense change, meaning one amino acid in the CETP protein is swapped for another. In human carriers, this swap is associated with greater CETP protein in the blood and lower HDL cholesterol. Think of it as a slightly more aggressive setting on the cholesterol-shuffling machine.

Sepsis Survival

The clearest human evidence for this specific variant comes from studies of people who developed sepsis, a life-threatening response to infection. Across seven sepsis cohorts including the UK Biobank, Copenhagen studies, iSPAAR, ICU groups, and trial populations, carrying the gain-of-function CETP variant rs1800777 was tied to roughly 44 percent higher 28-day mortality compared with non-carriers (hazard ratio 1.44, 95% CI 1.22-1.70).

Supporting this, a polygenic score that mimics genetic CETP reduction was associated with lower sepsis mortality, with hazard ratios of 0.77 in the UK Biobank and 0.60 in iSPAAR per 1 mmol/L higher HDL-C. The pattern across these studies is consistent: more CETP activity during sepsis tracks with worse survival, less activity tracks with better.

What this means for you: if you carry the variant, it does not predict that you will get sepsis. It does suggest that, if you ever do face a serious bloodstream infection, your biology may be working against you, and that fact is worth your treating clinicians knowing.

Sepsis-Associated Kidney Injury

A separate human study of 806 sepsis patients across two cohorts found that the rs1800777-A allele was associated with abnormally low HDL-C, higher CETP mass in the blood, and increased risk of clinically significant sepsis-associated acute kidney injury. This is the same gain-of-function pattern: more CETP activity, lower HDL, more organ damage when the body is under acute stress.

Lipids and Long-Term Cardiovascular Risk

The picture for everyday cardiovascular risk is more nuanced and points in the opposite direction. Human research on CETP genetics as a whole shows that people with naturally lower CETP activity (from protein-truncating variants or the common TaqIB B2 allele) tend to have higher HDL-C, lower LDL-C, and lower coronary heart disease risk. In one large analysis, CETP protein-truncating carriers had a summary odds ratio of 0.70 for coronary heart disease.

Conversely, Mendelian randomization work has shown that for each 1 microgram per milliliter higher genetically determined CETP concentration, HDL-C falls by about 0.23 mmol/L, with a directional signal toward higher coronary artery disease odds (about 8 percent, 95% CI 0.94-1.23) that did not reach statistical significance in that specific analysis. The Arg468Gln variant sits on the higher-CETP side of this spectrum, which fits a more atherogenic lipid pattern, though direct outcome studies of this specific variant in long-term cardiovascular endpoints are limited.

Why the Picture Looks Complicated

If you read about CETP for the first time, you may notice that the same biology that seems protective for the heart (low CETP, high HDL) looks harmful for the eyes (higher age-related macular degeneration risk in genetic CETP deficiency) and that high CETP during sepsis is harmful even though it raises LDL. This is not a paradox once you know the framework: CETP is a regulator of how cholesterol moves between particles, not a simple good-or-bad number. Different organs and different acute conditions react to that shuffling differently, which is why this genotype is a risk-pattern marker rather than a single-disease test.

One-Time Result, Lifetime Use

Your genotype at this position is fixed at conception. There is no need to retest the variant itself. Where the value compounds is in the companion testing you do over the years: standard lipid panels, ApoB, HDL particle measures, and inflammatory markers all become more meaningful once you know your underlying CETP setting. Pair a baseline lipid panel with this genotype, then retest those downstream lipids at least annually, or every three to six months if you are actively making changes.

Treat this as a one-time read that informs a long-running conversation. The number does not move, but the way you use it changes as you learn more about the rest of your cardiometabolic picture.

When the Result Can Be Misleading

• Variant panel coverage: this test detects only the p.Arg468Gln (rs1800777) change. A negative result does not rule out other rare CETP variants that may also influence CETP activity or HDL.
• Ancestry and allele frequency: the rs1800777 variant is uncommon overall, and its frequency differs between populations. The clinical meaning of being a carrier or non-carrier depends partly on your genetic ancestry.
• Variants of uncertain significance: if your lab reports an unexpected CETP change alongside the targeted variant, that finding may not yet have a clear clinical meaning.
• Clinical-grade vs direct-to-consumer: a result from a consumer testing service is a screening flag, not a clinical diagnosis. Confirmation by a clinical-grade method is appropriate before any major decisions.

What an Unexpected Result Should Make You Do

If you carry the gain-of-function variant, the action is not to retest the gene. It is to tighten the rest of your cardiometabolic workup. Pair this result with a full lipid panel including ApoB, a fasting glucose and HbA1c, and an inflammatory marker like hs-CRP (high-sensitivity C-reactive protein, a measure of low-grade inflammation linked to heart disease). If your HDL runs persistently low and your ApoB is elevated, a lipidologist or preventive cardiologist can help you build an aggressive plan.

Make sure the variant is documented in your medical record, and let your primary care clinician know it exists. If you are ever hospitalized for a severe infection, that single line in your chart may matter for how aggressively your care team monitors HDL, organ function, and overall trajectory. First-degree relatives may want to consider testing for the same variant, because it is inherited.